#United States #New York #Pomerantz #ImmunityBio #FDA Warning

Investor Alert: Class Action Filed Against ImmunityBio

The Pomerantz Law Firm has recently brought attention to a class action lawsuit filed against ImmunityBio, Inc. (NASDAQ: IBRX). This lawsuit particularly targets investors who have experienced losses due to potentially unlawful business practices by the company. Investors who purchased ImmunityBio securities during the specified Class Period are encouraged to step forward, especially given the looming deadline for submissions by May 26, 2026.

Understanding the Lawsuit

The class action is concerned with allegations that ImmunityBio and its executive management engaged in practices that may have amounted to securities fraud. Specifically, it calls into question the company's promotional activities regarding its bladder-cancer treatment drug, Anktiva, particularly after a warning issued by the U.S. Food and Drug Administration (FDA) on March 24, 2026. The FDA criticized ImmunityBio for continuing to promote Anktiva in a misleading manner despite previous alerts. This led to a dramatic drop in the company's stock price, decreasing by 21.12% to $7.41 following the public release of the FDA's warning letter.

The firm managing the case, Pomerantz LLP, with a legacy of over 85 years in handling corporate, securities, and antitrust litigation, has a proven track record in advocating for the rights of defrauded investors. Past victories include significant financial recoveries for those affected by corporate misconduct, indicating that potential plaintiffs may indeed have a viable claim.

Participating in the Class Action

Investors believing they have been affected are encouraged to contact Danielle Peyton at Pomerantz LLP. It is recommended that they provide their mailing address, phone number, and the total number of acquired shares to better facilitate the initiation of their claim. Detailed information about the litigation can also be accessed through Pomerantz's official website, illustrating how to become involved in the lawsuit, further ensuring that the rights of shareholders are preserved and represented in court.

Conclusion

Given the recent developments concerning ImmunityBio's business practices and regulatory scrutiny from the FDA, those who have lost money during the Class Period have a critical window of opportunity to join the class action lawsuit. As May 26, 2026, approaches, it is imperative for affected investors to act swiftly to safeguard their potential claims and hold the involved parties accountable for their actions. There’s no doubt that this lawsuit marks an important step in ensuring that corporate transparency and ethical standards are upheld in the pharmaceutical industry.